Despite the identification of many frequently mutated genes as potential therapeutic targets in HCC, the multikinase inhibitor Sorafenib that inhibits vascular endothelial growth factor receptor (VEGFR) 1–3, platelet-derived growth factor receptor (PDGFR) beta, c-KIT, and RAF/mitogen-activated protein/MEK was the sole drug approved for the treatment of advanced HCC between 2007 and 2016 with a response rate of less than 5% and an extended median overall survival of 2.5 months (Llovet et al. 2008). The gene discussed is PDGFRB; the disease is hepatocellular carcinoma.